Tianqiang Song
机构：Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0001-5979-5213
发表论文 146 篇 · 总被引 9025 次 · h-index 29
代表论文
- Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · The Lancet. Gastroenterology & hepatology · 被引 46)
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 43)
- Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation (2024 · Cell Reports Medicine · 被引 26)
- Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial (2024 · Neoplasma · 被引 22)
- Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
- Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study (2024 · Scientific Reports · 被引 9)